Literature DB >> 1312261

Reconstitution of enzymatic activity in hepatocytes of phenylalanine hydroxylase-deficient mice.

T J Liu1, M A Kay, G J Darlington, S L Woo.   

Abstract

Phenylketonuria (PKU) is a metabolic disorder secondary to a deficiency of the hepatic enzyme phenylalanine hydroxylase (PAH). The recent creation of a mouse strain for PAH deficiency has provided an excellent model system to explore the possibility of its phenotypic correction by hepatic gene therapy. A recombinant retrovirus containing the mouse PAH cDNA under the transcriptional control of the human CMV promoter was constructed and used to transduce hepatocytes isolated from PAH-deficient mice. Viral-transduced hepatocytes produced dramatically higher levels of mouse PAH mRNA as compared to control mock-infected hepatocytes. The PAH mRNA was translated efficiently into PAH protein that is capable of converting phenylalanine to tyrosine in vitro. These results demonstrate that the PAH-deficient mouse hepatocytes can be readily reconstituted by retroviral-mediated gene transduction, which is a crucial step towards somatic gene therapy for PKU.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1312261     DOI: 10.1007/bf01233451

Source DB:  PubMed          Journal:  Somat Cell Mol Genet        ISSN: 0740-7750


  11 in total

1.  Pseudotransduction of hepatocytes by using concentrated pseudotyped vesicular stomatitis virus G glycoprotein (VSV-G)-Moloney murine leukemia virus-derived retrovirus vectors: comparison of VSV-G and amphotropic vectors for hepatic gene transfer.

Authors:  M L Liu; B L Winther; M A Kay
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

Review 2.  Somatic gene therapy for phenylketonuria and other hepatic deficiencies.

Authors:  R C Eisensmith; S L Woo
Journal:  J Inherit Metab Dis       Date:  1996       Impact factor: 4.982

3.  Clinical therapeutics for phenylketonuria.

Authors:  Jaspreet Singh Kochhar; Sui Yung Chan; Pei Shi Ong; Lifeng Kang
Journal:  Drug Deliv Transl Res       Date:  2012-08       Impact factor: 4.617

4.  Low therapeutic threshold for hepatocyte replacement in murine phenylketonuria.

Authors:  Kelly Hamman; Heather Clark; Eugenio Montini; Muhsen Al-Dhalimy; Markus Grompe; Milton Finegold; Cary O Harding
Journal:  Mol Ther       Date:  2005-08       Impact factor: 11.454

5.  Complete correction of hyperphenylalaninemia following liver-directed, recombinant AAV2/8 vector-mediated gene therapy in murine phenylketonuria.

Authors:  C O Harding; M B Gillingham; K Hamman; H Clark; E Goebel-Daghighi; A Bird; D D Koeberl
Journal:  Gene Ther       Date:  2006-03       Impact factor: 5.250

6.  Expression of human phenylalanine hydroxylase activity in T lymphocytes of classical phenylketonuria children by retroviral-mediated gene transfer.

Authors:  C M Lin; Y Tan; Y M Lee; C C Chang; K J Hsiao
Journal:  J Inherit Metab Dis       Date:  1997-11       Impact factor: 4.982

Review 7.  Gene therapy for phenylketonuria.

Authors:  R C Eisensmith; S L Woo
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

Review 8.  State-of-the-art 2003 on PKU gene therapy.

Authors:  Zhaobing Ding; Cary O Harding; Beat Thöny
Journal:  Mol Genet Metab       Date:  2004-01       Impact factor: 4.797

9.  Hepatic gene therapy: adenovirus enhancement of receptor-mediated gene delivery and expression in primary hepatocytes.

Authors:  R J Cristiano; L C Smith; S L Woo
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205

Review 10.  Progress toward cell-directed therapy for phenylketonuria.

Authors:  Co Harding
Journal:  Clin Genet       Date:  2008-05-21       Impact factor: 4.438

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.